{
    "clinical_study": {
        "@rank": "95798", 
        "arm_group": [
            {
                "arm_group_label": "Discontinue Tenofovir DF treatment", 
                "arm_group_type": "Other", 
                "description": "Subjects will not receive tenofovir during the 72 week study period"
            }, 
            {
                "arm_group_label": "Tenofovir DF treatment", 
                "arm_group_type": "Other", 
                "description": "Subjects will receive 300 mg of tenofovir DF once a day during the 72 week study period"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective randomized, open-label, phase IV clinical trial to learn the effects,\n      good and/or bad, of discontinuing or continuing Tenofovir DF treatment for 72 weeks in\n      participants with chronic hepatitis B infection whose immune system is controlling the\n      amount of virus levels in the blood for at least 12 months of tenofovir DF therapy.\n\n      About 66 adult men and women will participate in this study from University Health Network\n      which includes the Toronto Western Hospital for about 72 weeks."
        }, 
        "brief_title": "Sustained Off-treatment Response After HBeAg Seroconversion in HBeAg-Pos Chronic HepB Patients Treated With Tenofovir", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Chronic infection with the hepatitis B virus (HBV) is prevalent world-wide (estimated to\n      affect 360 million individuals).\n\n      Chronic hepatitis b may result in progressive liver disease that leads to cirrhosis,\n      end-stage liver disease and hepatocellular carcinoma (HCC). Chronic hepatitis B can also be\n      benign and non-progressive, evolving into an inactive carrier state that rarely leads to\n      significant liver injury or HCC. Over the last few years, several highly effective antiviral\n      agents have been developed and approved for use in the treatment of chronic hepatitis B.\n      Current therapy of chronic hepatitis B (CHB) aims at stopping progression to cirrhosis and\n      hepatocellular carcinoma.\n\n      This is a prospective randomized, open-label, phase IV clinical trial to learn the effects,\n      good and/or bad, of discontinuing or continuing Tenofovir DF treatment for 72 weeks in\n      participants with chronic hepatitis B infection whose immune system is controlling the\n      amount of virus levels in the blood for at least 12 months of tenofovir DF therapy.\n\n      About 66 adult men and women will participate in this study from University Health Network\n      which includes the Toronto Western Hospital for about 72 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  chronic hepatitis B (HBsAg positive >6 months\n\n          -  HBeAg negative and HBV DNA <200 IU/ml on at least 2 occasions over the last year\n             during tenofovir treatment\n\n          -  age >18 years\n\n          -  Adequate contraception for males and females during treatment and follow up; negative\n             pregnancy test (for women of childbearing potential) written informed consent\n\n        Exclusion Criteria:\n\n          -  treatment with any investigational drug within 30 days of screening\n\n          -  severe hepatitis activity as documented by ALT >10x ULN\n\n          -  creatinine clearance <70 ml/min\n\n          -  history of decompensated cirrhosis\n\n          -  co-infection with hepatitis C virus, hepatitis D virus or human immunodeficiency\n             virus (HIV)\n\n          -  other acquired or inherited causes of liver disease\n\n          -  alpha fetoprotein .50 ng/ml\n\n          -  hyper- or hypothyroidism\n\n          -  immune suppressive treatment within the previous 6 months\n\n          -  pregnancy, lactation\n\n          -  other significant medical illnesses that might interfere with this study\n\n          -  any medical condition requiring, or likely to require chronic systemic administration\n             of steroids, during the course of the study\n\n          -  substance abuse (alcohol (80 g/day)and inhaled drugs (past 2 years)\n\n          -  any other condition which in the opinion of the investigator would make the patient\n             unsuitable for enrollment, or could interfere with the patient participating in and\n             completing the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911156", 
            "org_study_id": "STOP Study", 
            "secondary_id": "GILEAD Sciences Canada, Inc."
        }, 
        "intervention": [
            {
                "arm_group_label": "Tenofovir DF treatment", 
                "description": "300 mg tenofovir once a day during the 72 week study period", 
                "intervention_name": "Continue Tenofovir DF treatment", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Discontinue Tenofovir DF treatment", 
                "description": "Discontinue Tenofovir DF Treatment", 
                "intervention_name": "Discontinue Tenofovir DF Treatment", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tenofovir", 
                "Tenofovir disoproxil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Chronic hepatitis B", 
        "lastchanged_date": "July 25, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5T 2S8"
                    }, 
                    "name": "University Health Network"
                }, 
                "investigator": {
                    "last_name": "Mahmoud Abu-Amara", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "catalina.coltescu@uhn.ca", 
                    "last_name": "Catalina Coltescu", 
                    "phone": "416-603-5914"
                }, 
                "contact_backup": {
                    "email": "mabuamar@uhnresearch.ca", 
                    "last_name": "Mahmoud Abu-Amara", 
                    "phone": "416-603-5914"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5T 2S8"
                    }, 
                    "name": "University Health Network"
                }, 
                "investigator": {
                    "last_name": "Harry Janssen, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Sustained Off-treatment Response After HBeAg Seroconversion in HBeAg-Positive Chronic Hep B Patients Treated With Tenofovir", 
        "overall_contact": {
            "email": "mabuamar@uhnresearch.ca", 
            "last_name": "Mahmoud Abu-Amara", 
            "phone": "416-603-5914"
        }, 
        "overall_official": {
            "affiliation": "University Heath Network", 
            "last_name": "Harry Janssen, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Sustained response, defined as the presence of an HBV DNA level <2000 IU/ml at week 48 in patients with a combined response at baseline", 
            "safety_issue": "Yes", 
            "time_frame": "Outcome of patients in whom tenofovir monotherapy is stopped at week 0 and of patients who continue to receive tenofovir monotherapy up till week 72"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911156"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University Health Network, Toronto", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Health Network, Toronto", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}